Related references
Note: Only part of the references are listed.Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: A cohort study
Sandra Feldt et al.
EUROPEAN JOURNAL OF CANCER (2012)
Sarcopenia Predicts Early Dose-Limiting Toxicities and Pharmacokinetics of Sorafenib in Patients with Hepatocellular Carcinoma
Olivier Mir et al.
PLOS ONE (2012)
Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer
Marcia S. Brose et al.
BMC CANCER (2011)
Radioiodine for remnant ablation and therapy of metastatic disease
Christoph Reiners et al.
NATURE REVIEWS ENDOCRINOLOGY (2011)
Tyrosine kinase inhibitor-induced hypothyroidism: incidence, etiology, and management
Rebecca L. Brown
TARGETED ONCOLOGY (2011)
Sorafenib-Induced Hypothyroidism Is Associated with Increased Type 3 Deiodination
Randa M. Abdulrahman et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: A prospective evaluation
Hideaki Miyake et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2010)
Drugs that suppress TSH or cause central hypothyroidism
Bryan R. Haugen
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma
Hendrieke Hoftijzer et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2009)
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
Scott M. Wilhelm et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Age influences TSH serum levels after withdrawal of 1-thyroxine or rhTSH stimulation in patients affected by differentiated thyroid cancer
Teresa Montesano et al.
BIOMEDICINE & PHARMACOTHERAPY (2007)
Influence of human body composition on serum peak thyrotropin (TSH) after recombinant human TSH administration in patients with differentiated thyroid carcinoma
MG Castagna et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Influence of body surface area on serum peak thyrotropin (TSH) levels after recombinant human TSH administration
G Vitale et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Thyroid-stimulating hormone and thyroid-stimulating hormone receptor structure-function relationships
MW Szkudlinski et al.
PHYSIOLOGICAL REVIEWS (2002)
Share Paper
